Valtropin (somatropin) – Summary of product characteristics - H01AC01

Updated on site: 10-Oct-2017

Medication nameValtropin
ATC CodeH01AC01
ManufacturerBioPartners GmbH
After reconstitution with 1.5 ml solvent, 1 ml contains: somatropin* 3.33 mg (corresponding to 10 IU)
* produced in Saccharomyces cerevisiae cells by recombinant DNA For a full list of excipients, see section 6.1.


Valtropin 5 mg/1.5 ml powder and solvent for solution for injection


One vial of powder contains 5 mg somatropin (corresponding to 15 IU).






Powder and solvent for solution for injection.



White or almost white powder. The solvent is a clear solution.


After reconstitution with the solvent provided, Valtropin has a pH of pproximately 7.5 and an

osmolality of approximately 320 mOsm/kg.










Therapeutic indications




Paediatric population




Long-term treatment of children (2 to 11 years old) and adolescents (12 to 18 years old) with


growth failure due to an inadequate secretion of normal endogenous growth hormone.


Treatment of short stature in children with Turner syndrome, confirmed by chromosome










Treatment of growth ret rdationproductin pre-pubertal children with chronic renal insufficiency.

Adult patients




Replacement therapy adults with pronounced growth hormone deficiency of either childhood-


or adult-onset aetiology.



Patients with severe growth hormone deficiency in adulthood are defined as patients with known hypothalamic-pituitary pathology and at least one additional known deficiency of a pituitary hormone not being prolactin. These patients should undergo a single dynamic test in order to diagnose or exclude a growth hormone deficiency. In patients with childhood-onset isolated growth hormone deficiency (no evidence of hypothalamic-pituitary disease or cranial irradiation), two dynamic tests should be recommended, except for those having low insulin-like growth factor-1 (IGF-1) concentrations (< 2 standard deviation score (SDS)), who may be considered for one test. The cut-off point of the dynamic test should be strict.

4.2 Posology and method of administration

Therapy with Valtropin should be initiated and monitored by physicians adequately experienced in the diagnosis and management of patients with growth hormone deficiency.


Special populations

The dosage and administration schedule should be individualised for each patient.

Dosage in paediatric population

Growth hormone deficiency in children

The recommended dosage is 0.025 - 0.035 mg/kg body weight per day.

Children with Turner syndrome

The recommended dosage is 0.045 - 0.050 mg/kg body weight per day, given as a subcutaneous injection.

Pre-pubertal children with chronic renal insufficiency

The recommended dosage is 0.045 - 0.050 mg/kg body weight per day, given as a subcutaneous injection.

Dosage in adult patients


Growth hormone deficiency in adults

The recommended starting dose is 0.15 - 0.30 mg/day, given as a subcutane us injection. A lower starting dose may be necessary in older and obese patients.

This dose should be gradually increased according to individual patient requirements based on the clinical response and serum IGF-1 concentrations. Total daily dose usually does not exceed 1 mg. IGF-1 concentrations should be maintained below the upper limit of the age-specific normal range.

The minimum effective dose should be used.



The dosage of somatropin should be decreased in caseslongerof persistent oedema or severe paresthesia, in

order to avoid the development of carpal tunnel sy drome.



Experience of prolonged treatment (over 5 years) with somatropin in adults is limited.



Experience of somatropin tre tment in patients above 60 years of age is limited. A lower starting dose

may be necessary older patients. Dose requirements may decline with increasing age.

Renal impairment

Currently available data on renal insufficiency are described in section 4.4, but no recommendation on a posology can be made.

Hepatic impairment

In patients with severe liver dysfunction a reduction of somatropin clearance has been noted. The clinical significance of this decrease is unknown.

Method of administration

Valtropin is administered by subcutaneous injection.

The injection sites should be varied in order to avoid lipo-atrophy.

For further information on reconstitution and administration see section 6.6.

4.3 Contraindications

-Hypersensitivity to the active substance or to any of the excipients (e.g. metacresol) (see section 4.4).

-Somatropin must not be used when there is any evidence of activity of a tumour. Intracranial tumours must be inactive and antitumour therapy must be completed prior to starting GH therapy. Treatment should be discontinued if there is evidence of tumour growth.

-Valtropin should not be used for growth promotion in children with closed epiphyses.

-Patients with acute critical illness due to complications following open heart or abdominal surgery, multiple accidental trauma, or patients having acute respiratory failure.

4.4 Special warnings and precautions for use

The maximum recommended daily dose should not be exceeded (see section 4.2).


There is no evidence to suspect that growth hormone replacement influences the recurrence rate or

regrowth of intracranial neoplasms, but standard clinical practice requiresauthorisedregular pituitary imaging in

patients with a history of pituitary pathology. A baseline scan is recommended in th se patients before instituting growth hormone replacement therapy.

Tumour control

If the patient has had a brain tumour, the patient should be re-examined frequently to make sure that the tumour has not come back.

In childhood cancer survivors, a higher risk of a second neoplasm (benign malignant) has been reported in patients treated with somatropin. Intracraniallongertumou s, in particular, were the most common of these second neoplasms.

Intracranial hypertension

In cases of severe or recurrent headache, visualnopr blems, nausea, and/or vomiting, a fundoscopy for papilloedema is recommended. If papilloedema is c nfirmed, a diagnosis of benign intracranial hypertension should be considered and, if appropriate, the growth hormone treatment should be discontinued. At present, there isproductinsufficient evidence to guide clinical decision making in patients with resolved intracranial hypertension. If growth hormone treatment is restarted, careful monitoring for symptoms of intracranial hypertensi n is necessary.

Insulin sensitivity

Thyroid function

Because humanMedicinalgrowth hormone may induce a state of insulin resistance, patients treated with somatropin should be mo itored for evidence of glucose intolerance.

Growth hormone increases the extrathyroidal conversion of T4 to T3 and may, as such, unmask incipient hypothyroidism. Monitoring of thyroid function should therefore be conducted in all patients. In patients with hypopituitarism, standard replacement therapy must be closely monitored when somatropin therapy is administered.

Slipped capital epiphyse

Patients with endocrine disorders, including growth hormone deficiency, may develop slipped capital epiphyses more frequently. Any child with the onset of a limp during growth hormone therapy should be evaluated.

Growth hormone deficiency after epiphyseal closure

Subjects who had been treated with growth hormone during childhood, until final height was attained, should be re-evaluated for growth hormone deficiency after epiphyseal closure before replacement therapy is commenced at the doses recommended for adults.

Treatment after the end of growth in children

For children, the treatment should be continued until the end of the growth has been reached. It is advisable not to exceed the recommended dosage in view of the potential risks of acromegaly, hyperglycaemia, and glucosuria.

Prader-Willi syndrome

Valtropin is not indicated for the treatment of patients with growth failure due to Prader-Willi syndrome unless they also have a diagnosis of growth hormone deficiency. There have been reports of sleep apnoea and sudden death after initiating growth hormone therapy in patients with Prader-Willi syndrome, who had one or more of the following risk factors: severe obesity, history of upper airway obstruction or sleep apnoea, or unidentified respiratory infection.

Renal insufficiency



Before instituting treatment with somatropin for growth retardation secondary to chronic renal

insufficiency, children should have been followed for one year to verify growth disturbance.

Conservative treatment for renal insufficiency (which includes control of acidosis,



hyperparathyroidism, and nutritional status for one year prior to the treatment) should have been

established and should be maintained during treatment. Treatment with somatropin should be

discontinued at the time of renal transplantation.



Gender and dosing



In order to reach the defined treatment goal, men may need lower grow

ormone doses than women.

Oral oestrogen administration increases the dose requirements in women. An increasing sensitivity to growth hormone (expressed as change in IGF-1 per growth hormone dose) over time may be observed, particularly in men. The accuracy of the growth hormone dose should therefore be controlled every

6 months.

Turner syndrome



Patients with Turner syndrome should be evaluated carefullylongerfor otitis media and other ear disorders

since these patients have an increased risk of ear r hearing disorders.

Pancreatitis in children





Children treated with somatropin have an increased risk of developing pancreatitis compared to adults treated with somatropin. Although rare, pancreatitis should be considered in somatropin-treated children who develop abdominal pain.

Accidental intramuscularMedicinalinjection

After accidental intramuscular injection, hypoglycaemia may appear. Any unwanted reaction should be followed. No spe ial treatment is recommended.

Sensitivity to metacresol

Valtropin should not be reconstituted with the supplied solvent for patients with a known sensitivity to metacresol. If sensitivity to the accompanying solvent occurs, the vials should be reconstituted with water for injections and used as a single use vial (see section 6.3).

4.5Interaction with other medicinal products and other forms of interaction

Excessive glucocorticoid therapy will inhibit the growth-promoting effect of human growth hormone. Patients with co-existing adrenocorticotropic hormone (ACTH) deficiency should have their glucocorticoid replacement dose carefully adjusted to avoid an inhibitory effect on growth.

In women taking oral oestrogens, a higher dose of somatropin may be required to achieve the treatment goal.

Patients taking insulin for diabetes mellitus should be carefully monitored during treatment with somatropin. An adjustment of the insulin dose may be required.

No data on fertility are available. Animal data showed

Data from an interaction study performed in growth hormone deficient adults, suggests that somatropin administration may increase the clearance of compounds known to be metabolised by cytochrome P450 isoenzymes. The clearance of compounds metabolised by cytochrome P 450 3A4 (e.g. sex steroids, corticosteroids, anticonvulsants and cyclosporine) may be especially increased resulting in lower plasma levels of these compounds. The clinical significance of this is unknown.

4.6 Fertility, pregnancy and lactation


For Valtropin no clinical data on exposed pregnancies are available. Animal studies are insufficient with respect to effects on pregnancy, embryofoetal development, parturition or postnatal development (see section 5.3). Therefore Valtropin should not be used during pregnancy unless clearly necessary.



There have been no clinical studies conducted with Valtropin in breast-feeding women. It is not known whether somatropin is excreted in human milk. Therefore caution should be x rcised when Valtropin is administered to breast-feeding women.

no effect on fertili y parameters.

4.7 Effects on ability to drive and use machines

Valtropin has no or negligible influence on the ability tolongerdrive and use machines.

4.8 Undesirable effects

Summary of the safety profile



The most common frequent adverse reactions are associated with the injection site, of endocrine nature, and headache, paresthesiaproductand joint pain and disorder (arthralgia) in adults.

During clinical studies 128 children (98 children with growth hormone deficiency and 30 with Turner syndrome) were exposed to Valt opin. The safety profile of Valtropin observed in these clinical

studies was consistent with that re orted with the reference medicinal product used in these studies The followingMedicinaladverse reactions and their frequencies have been observed under treatment with somatropin based on published information:

and other somatropin cont ining medicinal products.

Very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare

(≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the available data), including isolated reports

Tabulated summary of adverse reactions

Neoplasms benign, malignant and


unspecified (including cysts and polyps)

Uncommon: Neoplasm malignant, neoplasm

Blood and lymphatic system disorders

Uncommon: Anaemia

Immune system disorders

Common: Antibody building


Not known: Single case of acute hypersensitivity


involving urticaria and pruritus

Endocrine disorders

Common: Hypothyroidism

Metabolism and nutrition disorders

Common: Glucose tolerance impaired


Common: Mild hyperglycaemia (1% in children;




1% - 10% in adults)




Uncommon: Hypoglycaemia, hyperphosphatemia



Rare: Diabetes mellitus



Not known: Insulin resistance

Psychiatric disorders


Uncommon: Personality disorder

Nervous system disorders


Very common: Headache in adults



Very common: Paresthesia in adults



Common: Hypertonia



Common: Insomnia in adults



Common: Carpal tunnel syndrome in adults



Uncommon: Carpal tunnel syndrome in children



Uncommon: Nystagmus



Rare: Neuropathy, intracranial pressure increased








Rare: Benign intracranial hypertension



Rare: Paresthesia in children



Very rare: Insomnia in children

Eye disorders


Uncommon: Papilloedema, diplopia

Ear and labyrinth disorders


Uncommon: Vertigo


Cardiac disorders


Common: Hypertension in adults








Uncommon: Tachyca dia



Rare: Hypertension in children

Respiratory, thoracic and mediastinal






Comm n: Dyspnoea in adults








C mm n: Sleep apnoea in adults

Gastrointestinal disorders


U common: Vomiting, abdominal pain, flatulence, nausea



Rare: Diarrhoea







Uncommon: Lipodystrophy, skin atrophy, exfoliative

Skin and subcutaneous tissue disorders

dermatitis, urticaria, hirsutism, skin hypertrophy

Musculoskeletal and connective tissue






Very common: Arthralgia in adults



Common: Arthralgia in children





Common: Myalgia




Uncommon: Muscle atrophy, bone pain



Uncommon: Urinary incontinence, haematuria, polyuria,

Renal and urinary disorders


urine frequency/pollakiuria, urine abnormality

Reproductive system and breast disorders

Uncommon: Genital discharge



Uncommon: Gynaecomastia in adults



Very rare: Gynaecomastia in children

General disorders and administration site






Very common: Oedema, peripheral oedema in adults



Common: Oedema, peripheral oedema in children



Common: Injection site reactions, asthenia



Uncommon: Injection site atrophy, injection site



haemorrhage, injection site mass, hypertrophy, weakness



in children




Rare: Renal function test abnormal

Description of selected adverse reactions

4.9 Overdose

In a clinical study with Valtropin, 3% of children with growth hormone deficiency developed antibodies to somatropin. The binding capacity of these antibodies was low and there was no effect on growth rate. Testing for antibodies to somatropin should be carried out in any patient who fails to respond to therapy.

Anti-host cell protein (anti-S. cerevisiae) antibodies were uncommon in patients treated with Valtropin. The generation of such antibodies with low binding capacity is unlikely to be clinically relevant. In contrast to bacteria (E. coli), yeast has not been described to elicit adjuvant effects modifying the immunological response.

Paediatric population

Mild and transient oedema was observed early during the course of treatment with somatropin.

Adult patients

In adult patients with adult-onset growth hormone deficiency, oedema, muscle pain, joint pain and

disorders were reported early in therapy and tended to be transient.

excess human growth hormone. Treatment is symptomatic and supportive. There is no antidote for somatropin overdose. It is recommended to monitor thyroid function following an overdose.

Acute overdose could lead initially to hypoglycaemia and subsequentlyauthorisedto hyperglycaemia. Long-term overdose could result in signs and symptoms of acromegaly consistent wi known effects of





Pharmacodynamic properties







Pharmacotherapeutic group: Pituitary and hypothalamic hormones and analogues, somatropin and somatropin agonists; ATC code: H01AC01

Somatropin is a polypeptide hormone of recombinant DNA origin. It has 191 amino acid residues and

a molecular weight of 22,125 dalt

ns. The amino acid sequence of the medicinal product is identical to

that of human growth hormone of

ituitary origin. Valtropin is synthesised in yeast cells



(Saccharomyces cerevisiae).


The biological effects of somatropin are equivalent to those of human growth hormone of pituitary origin.

The most promin nt effect of somatropin is that it stimulates the growth plates of long bones. Additionally, it promotes cellular protein synthesis and nitrogen retention.

Somatropin stimulates lipid metabolism; it increases plasma fatty acids and high-density lipoprotein (HDL)-cholesterols, and decreases total plasma cholesterol.

Somatropin therapy has a beneficial effect on body composition in growth hormone-deficient patients, in that body fat stores are reduced and lean body mass is increased. Long-term therapy in growth hormone-deficient patients increases bone mineral density.

Somatropin may induce insulin resistance. Large doses of somatropin may impair glucose tolerance.

Clinical studies

The efficacy and safety of Valtropin has been assessed in a randomised, double-blind, parallel, controlled Phase III study in children with growth hormone deficiency. There were no relevant

differences between Valtropin and the reference medicinal product with regard to height velocity and height velocity SDS.

An open single-arm Phase III study investigating the efficacy and safety of treatment with Valtropin in girls with short stature associated with Turner syndrome showed a significant effect of study treatment on height velocity.

5.2 Pharmacokinetic properties

A double-blind, randomised, single dose, crossover study in 24 healthy volunteers showed that the pharmacokinetic profile of Valtropin was comparable to that of the reference medicinal product. Subcutaneous administration of 0.073 mg/kg body weight of Valtropin resulted in a Cmax of 43.97 ng/ml and an AUC0-24 h of 369.90 ng·h/ml. Cmax was reached at 4 h and t½ was 3 h.

5.3 Preclinical safety data

Non-clinical data reveal no special hazard for humans based on conventional studi s with Valtropin of repeated dose toxicity, genotoxicity and reproductive toxicity studies.

Animal studies with Valtropin are not sufficient to assess the reproductive xicity potential. From


reproductive toxicity studies performed with other somatropin medicinal products there is no evidence

of an increased risk of adverse reactions for the embryo or foetus.







Long-term studies for carcinogenicity have not been perform d. There are no specific local tolerance

studies in animals after subcutaneous injection of Valtropin. However, in single and repeat-dose

general toxicity studies no adverse reactions at the injection sites were reported.






List of excipients















Sodium hydroxide (for pH adjustment)

Hydrochloric acid (for pH adjustment).

Sodium dihydrogenMedicinalphosph te nhydrous

Disodium phosphate hydrous



Water for injections.


In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

6.3Shelf life

3 years

After first opening or following reconstitution with the solvent provided:

After reconstitution with the solvent provided, chemical and physical in-use stability has been demonstrated for 21 days at 2°C - 8°C (refrigerator).

For use and handling

Following reconstitution with water for injections:

After reconstitution with water for injections, the medicinal product must be used immediately and must be used as a single use vial. If not used immediately, in-use storage times and conditions prior to use would normally not be longer than 24 hours at 2°C - 8°C (refrigerator), unless reconstitution has taken place in controlled and validated aseptic conditions.

6.4 Special precautions for storage

Store in a refrigerator (2°C - 8°C). Do not freeze.

For the purpose of transport and/or ambulatory use, the non-reconstituted medicinal product can be kept at room temperature (not above 25°C) for one single period of up to 4 weeks before use.

The date of refrigerator removal and the new expiry date should be written on the outer carton. At the end of the new expiry date, the medicinal product should have been used or be disposed of.

For storage conditions of the reconstituted medicinal product, see section 6.3.

6.5 Nature and contents of container

5 mg of powder in a vial (Type I glass) closed with a stopper (butyl rubber) and flip-off cap (aluminium plastic).

1.5 ml of solvent in a pre-filled syringe (Type I glass) closed with tip cap (FluroTec coated butyl




Pack size of 1 vial and 1 pre-filled syringe.


6.6 Special precautions for disposal and other handlinglonger


Detailed instructions for the handling of the medicinalno product are given at the end of the package


metacresol (see section 4.3). If sensitivity to the accompanying solvent occurs, the vials should be

Valtropin should not be reconstituted with the supplied solvent for patients with a known sensitivity to reconstitutedMedicinalwith water for injections and used as a single use vial.

Reconstitution with the solvent provided

Each vial of Valtropin should be reconstituted using the accompanying solvent. The solvent should not be used if it is discoloured or cloudy. The solvent should be injected into the vial by aiming the stream of liquid against the glass wall. Following reconstitution, the vial should be swirled with a GENTLE rotary motion until the contents are completely dissolved. DO NOT SHAKE. The resulting solution should be clear, without particulate matter. If the solution is discoloured, cloudy or contains particulate matter, the contents MUST NOT be injected. Before and after every injection, the septum of the vial should be wiped with alcohol to prevent contamination of the contents by repeated needle insertions. If reconstituted with the solvent, then the solution is for multidose use (see section 6.3).

Reconstitution with water for injections

After reconstitution with water for injections the medicinal product must be used immediately (see section 6.3) and the solution is for single use only.


Sterile disposable syringes and needles should be used for administration of Valtropin. The volume of the syringe should be small enough so that the prescribed dose can be withdrawn from the vial with reasonable accuracy.


Any unused medicinal product or waste material should be disposed of in accordance with local requirements.


BioPartners GmbH

Kaiserpassage 11

D-72764 Reutlingen






Detailed information on this medicinal product is avai ab n the website of the European Medicines

Agency http://www.ema.europa.eu/













  • Help
  • Get it on Google Play
  • About
  • Info on site by:

  • Presented by RXed.eu

  • 27558

    prescription drugs listed